Equillium, Inc. (NASDAQ:EQ) Short Interest Up 620.6% in February

Equillium, Inc. (NASDAQ:EQ) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 672,300 shares, an increase of 620.6% from the January 31st total of 93,300 shares. Approximately 3.9% of the shares of the company are sold short. Based on an average daily trading volume, of 771,000 shares, the days-to-cover ratio is presently 0.9 days.

Equillium Stock Down 0.2 %

Equillium stock traded down $0.00 during trading hours on Thursday, hitting $0.76. The stock had a trading volume of 44,859 shares, compared to its average volume of 1,233,462. Equillium has a one year low of $0.49 and a one year high of $2.99. The stock has a market cap of $27.05 million, a price-to-earnings ratio of -5.45 and a beta of 1.79. The business’s 50 day simple moving average is $0.74 and its 200-day simple moving average is $0.82.

Institutional Investors Weigh In On Equillium

A hedge fund recently bought a new stake in Equillium stock. Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium makes up about 5.2% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 4th largest holding. Takeda Pharmaceutical Co. Ltd. owned about 5.15% of Equillium as of its most recent SEC filing. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.